abstract |
The present invention relates to soluble, recombinant CD40L variant proteins that may be expressed solubly in E. coli . The variants of the present invention may substantially reduced binding to alpha IIb-beta3 integrin, act as CD40L antagonists or agonists, and methods for generating the same. |